Criteria in Risk Stratification of Lung Neuroendocrine Tumors (NETs)
05/31/2017 - 05/31/2018
Oncology Briefings™ is an online interactive monograph that will provide an overview of the biology of lung neuroendocrine tumors (NETs) in addition to a review of recent data regarding emerging and novel treatment strategies in patients with lung NETs. This format includes a brief presentation of clinical science, and features discussion by a national thought leader to provide key take-home points and pearls for practice that will place the content into perspective. Audio sidebars and tables provide supporting evidence.
This activity is directed toward oncology healthcare professionals who treat patients with lung NETs, including medical oncologists, radiology oncologists, and surgical oncologists. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the management of patients with lung NETs are also invited to participate.
At the conclusion of this activity, participants should be better prepared to:
- Review the biology of neuroendocrine tumors (NETs) of the lung
- Discuss the current and emerging techniques used in the differential diagnosis and monitoring of patients with lung NETs
- Assess current and emerging therapeutic options as well as sequential strategies for the treatment of patients with lung NETs
- Describe the importance of a multidisciplinary approach in accurately diagnosing and treating patients with lung NETs
Leading NET cancer expert Jonathan R. Strosberg, MD, associate professor and head of the Gastrointestinal Department Research Program at H. Lee Moffitt Cancer Center, Tampa, Florida, answers key questions supported by the presentation of clinical science about lung NETs. This first of 3 PER Pulse™ Recaps from this program focuses on important criteria in the stratification of lung NETs.